JP2023055871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055871A5 JP2023055871A5 JP2023014793A JP2023014793A JP2023055871A5 JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5 JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- composition
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024189529A JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050948P | 2014-09-16 | 2014-09-16 | |
| US62/050,948 | 2014-09-16 | ||
| US201462067642P | 2014-10-23 | 2014-10-23 | |
| US62/067,642 | 2014-10-23 | ||
| US201462083929P | 2014-11-25 | 2014-11-25 | |
| US62/083,929 | 2014-11-25 | ||
| US201462093141P | 2014-12-17 | 2014-12-17 | |
| US201462093124P | 2014-12-17 | 2014-12-17 | |
| US62/093,141 | 2014-12-17 | ||
| US62/093,124 | 2014-12-17 | ||
| JP2020166883A JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166883A Division JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Division JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023055871A JP2023055871A (ja) | 2023-04-18 |
| JP2023055871A5 true JP2023055871A5 (OSRAM) | 2023-08-08 |
| JP7580506B2 JP7580506B2 (ja) | 2024-11-11 |
Family
ID=54105801
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2023014793A Active JP7580506B2 (ja) | 2014-09-16 | 2023-02-02 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10676523B2 (OSRAM) |
| EP (1) | EP3193929B1 (OSRAM) |
| JP (4) | JP2017538660A (OSRAM) |
| KR (2) | KR20240141862A (OSRAM) |
| CN (1) | CN107074950A (OSRAM) |
| AU (3) | AU2015316993B2 (OSRAM) |
| CA (1) | CA2959463A1 (OSRAM) |
| DK (1) | DK3193929T3 (OSRAM) |
| ES (1) | ES2742456T3 (OSRAM) |
| HU (1) | HUE044704T2 (OSRAM) |
| IL (1) | IL250672B (OSRAM) |
| PL (1) | PL3193929T3 (OSRAM) |
| SG (2) | SG10202007781TA (OSRAM) |
| WO (1) | WO2016041947A1 (OSRAM) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2538973A2 (en) | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Stable antibody containing compositions |
| WO2012172102A1 (en) | 2011-06-17 | 2012-12-20 | Novo Nordisk A/S | Selective elimination of erosive cells |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| HUE051193T2 (hu) | 2014-09-16 | 2021-03-01 | Innate Pharma | Gátlási reakcióút semlegesítése limfocitákban |
| EP3659625A1 (en) | 2014-10-23 | 2020-06-03 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| CN107849148B (zh) | 2015-05-21 | 2023-09-19 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| LT3405495T (lt) | 2016-01-21 | 2021-08-10 | Innate Pharma | Inhibitorių kelių neutralizavimas limfocituose |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR20230173745A (ko) | 2016-10-21 | 2023-12-27 | 이나뜨 파르마 에스.에이. | 항-kir3dl2 작용제에 의한 치료 |
| CN113896792B (zh) | 2017-05-12 | 2025-08-22 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
| AU2018298673A1 (en) * | 2017-07-10 | 2019-12-19 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| KR102425983B1 (ko) | 2017-10-13 | 2022-07-29 | 하푼 테라퓨틱스, 인크. | 삼중특이적 단백질 및 사용 방법 |
| EA202092147A1 (ru) * | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| US12209126B2 (en) | 2018-05-15 | 2025-01-28 | Medimmune Limited | Treatment of cancer |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| IL281683B2 (en) | 2018-09-25 | 2023-04-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
| WO2020094071A1 (zh) * | 2018-11-07 | 2020-05-14 | 上海怀越生物科技有限公司 | Nkg2a抗体及其制备方法和应用 |
| JP7520003B2 (ja) | 2018-11-16 | 2024-07-22 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｎｋｇ２ａ抗体およびその使用 |
| KR20220032513A (ko) * | 2019-03-29 | 2022-03-15 | 드렌 바이오, 인크. | 거대 과립 림프구 및 자연 살해 세포 수준을 감소시키는 방법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN114599372A (zh) | 2019-11-04 | 2022-06-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| WO2021219048A1 (zh) * | 2020-04-30 | 2021-11-04 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN115551893A (zh) * | 2020-05-08 | 2022-12-30 | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 靶向自然杀伤细胞的嵌合抗原受体(car) |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| KR20230104611A (ko) | 2020-09-30 | 2023-07-10 | 드렌 바이오, 인크. | 항-cd94 항체 및 이의 사용 방법 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| JP2024520577A (ja) * | 2021-06-01 | 2024-05-24 | レ ラボラトワール セルヴィエ | 抗ｎｋｇ２ａ抗体及び組成物 |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| JP2025518785A (ja) | 2022-06-02 | 2025-06-19 | ブリストル－マイヤーズ スクイブ カンパニー | 抗体組成物及びその使用方法 |
| WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024150017A1 (en) | 2023-01-13 | 2024-07-18 | Akrivia Biomedics Limited | Method of profiling diseases |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025250011A1 (en) | 2024-05-29 | 2025-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment for cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
| MX2007007935A (es) | 2004-12-28 | 2007-12-06 | Innate Pharma Sa | Anticuerpos monoclonales contra nkg2a. |
| CN101107269B (zh) * | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| MX2008015830A (es) * | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| JP5774312B2 (ja) | 2008-01-24 | 2015-09-09 | ノボ・ノルデイスク・エー／エス | ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体 |
| US20110033389A1 (en) | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
| EP2538973A2 (en) | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Stable antibody containing compositions |
| WO2012172102A1 (en) | 2011-06-17 | 2012-12-20 | Novo Nordisk A/S | Selective elimination of erosive cells |
| EP3186282A1 (en) | 2014-08-28 | 2017-07-05 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| HUE051193T2 (hu) | 2014-09-16 | 2021-03-01 | Innate Pharma | Gátlási reakcióút semlegesítése limfocitákban |
| EP3659625A1 (en) * | 2014-10-23 | 2020-06-03 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| LT3405495T (lt) | 2016-01-21 | 2021-08-10 | Innate Pharma | Inhibitorių kelių neutralizavimas limfocituose |
| EA202092147A1 (ru) | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
| US12209126B2 (en) | 2018-05-15 | 2025-01-28 | Medimmune Limited | Treatment of cancer |
-
2015
- 2015-09-15 SG SG10202007781TA patent/SG10202007781TA/en unknown
- 2015-09-15 HU HUE15763016 patent/HUE044704T2/hu unknown
- 2015-09-15 KR KR1020247031251A patent/KR20240141862A/ko active Pending
- 2015-09-15 SG SG11201701387SA patent/SG11201701387SA/en unknown
- 2015-09-15 KR KR1020177008837A patent/KR20170068458A/ko not_active Ceased
- 2015-09-15 AU AU2015316993A patent/AU2015316993B2/en active Active
- 2015-09-15 WO PCT/EP2015/071073 patent/WO2016041947A1/en not_active Ceased
- 2015-09-15 CN CN201580050103.1A patent/CN107074950A/zh active Pending
- 2015-09-15 JP JP2017514485A patent/JP2017538660A/ja active Pending
- 2015-09-15 PL PL15763016T patent/PL3193929T3/pl unknown
- 2015-09-15 ES ES15763016T patent/ES2742456T3/es active Active
- 2015-09-15 US US15/511,792 patent/US10676523B2/en active Active
- 2015-09-15 DK DK15763016.1T patent/DK3193929T3/da active
- 2015-09-15 CA CA2959463A patent/CA2959463A1/en active Pending
- 2015-09-15 EP EP15763016.1A patent/EP3193929B1/en active Active
-
2017
- 2017-02-19 IL IL250672A patent/IL250672B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/894,937 patent/US20200299383A1/en not_active Abandoned
- 2020-10-01 JP JP2020166883A patent/JP2021008487A/ja active Pending
-
2021
- 2021-04-08 US US17/225,160 patent/US12037392B2/en active Active
- 2021-06-07 AU AU2021203744A patent/AU2021203744B2/en active Active
-
2023
- 2023-02-02 JP JP2023014793A patent/JP7580506B2/ja active Active
-
2024
- 2024-07-15 US US18/772,517 patent/US20240368281A1/en active Pending
- 2024-10-29 JP JP2024189529A patent/JP2025016606A/ja active Pending
-
2025
- 2025-07-17 AU AU2025205563A patent/AU2025205563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055871A5 (OSRAM) | ||
| JP2025016606A5 (OSRAM) | ||
| KR101905208B1 (ko) | Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물 | |
| TWI436770B (zh) | 包含專一性辨識ｃｄ３８之抗體及阿糖胞苷（ｃｙｔａｒａｂｉｎｅ）之抗腫瘤組合 | |
| TWI457346B (zh) | 包含專一性辨識ｃｄ３８之抗體及環磷醯胺（ｃｙｃｌｏｐｈｏｓｐｈａｍｉｄｅ）之抗腫瘤組合 | |
| KR101733252B1 (ko) | Ｃｄ３８을 특이적으로 인식하는 항체 및 멜팔란을 함유하는 항종양 조합물 | |
| JP2009518441A5 (OSRAM) | ||
| JP2015172049A (ja) | Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ | |
| HK1164152A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine | |
| HK1164154B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide | |
| HK1185022B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| HK1185022A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| HK1164165B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan | |
| JPWO2021038097A5 (OSRAM) |